Related references
Note: Only part of the references are listed.A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer A Hoosier Oncology Group Study
Higinia R. Cardenes et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC)
J. C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Patrick J. Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Richard Kim
LANCET ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Mark P. Callery et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
Florence Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
